08.15.13
Boehringer Ingelheim
1H Revenues: $9.2 billion (+3%)
Comments: Pharmaceutical sales were $6.9 billion (+4%) in the first half, driven by Pradaxa (+28%), newly launched Trajenta, and Spiriva (+4%). OTC medicines grew by an adjusted 8% to $926.1 million. Biopharmaceuticals sales were down 21% to $218.5 million as a result of third party supply contracts ending in the reporting period.
1H Revenues: $9.2 billion (+3%)
Comments: Pharmaceutical sales were $6.9 billion (+4%) in the first half, driven by Pradaxa (+28%), newly launched Trajenta, and Spiriva (+4%). OTC medicines grew by an adjusted 8% to $926.1 million. Biopharmaceuticals sales were down 21% to $218.5 million as a result of third party supply contracts ending in the reporting period.
